Preclinical study reveals new cream may prevent or slow growth of some common skin cancers
PHILADELPHIA – A topical cream activated the skin’s immune defenses and suppressed tumor growth in two preclinical models of cutaneous squamous cell carcinoma (cSCC), one of the most common cancers in the world, according to a study published today in the Journal of Clinical Investigation. Developed by researchers at the Perelman School of Medicine at the University of Pennsylvania, the cream works by blocking LSD1, an enzyme that suppresses immune‑activating pathways in the skin.
“What’s ...